>NEWSROOM >Press Releases >2011 >Takeda and Samyang Form Research Collaboration in Novel DDS ...

Takeda and Samyang Form Research Collaboration in Novel DDS Platform Technology for RNAi Therapeutics

Osaka, Japan and Seoul, Korea –April 13, 2011 – Takeda Pharmaceutical Company Limited (“Takeda”) and Samyang Corporation (“Samyang”) today announced that they have formed a research collaboration agreement for discovering a novel DDS platform technology for RNAi therapeutics.

Samyang has biopolymer technology that is considered to serve as a platform for novel DDS technology. Under the terms of the agreement, Takeda and Samyang will conduct research collaboratively to develop novel DDS technology for RNAi therapeutics based on Samyang’s technology in three years, and more if necessary. Takeda will make an upfront payment and bear research costs during the collaboration period. Takeda will also make development milestone payments and pay sales-based royalties for marketed products under the terms thereof.

“We expect that the great synergy between our high-level DDS expertise and Takeda’s proven strength in pharmaceutical research and development will lead to RNAi therapeutics of high added-value,” said Cheolho Kwak, COO, Bio & Pharmaceuticals Group of Samyang.

“Takeda has enhanced the next-generation drug discovery platform technologies including antibody medicine, nucleic acid medicine and regenerative medicine,” said Shigenori Ohkawa, a member of the Board and Executive Vice President, Chief Scientific Officer of Takeda. “We are delighted to strengthen our pipeline in RNAi therapeutics through this research collaboration with Samyang who has a proven track record in cutting-edge biopolymer-based DDS technology.”

About RNA interference (RNAi)

RNAi (RNA interference) therapeutics is a type of nucleic acid medicine. The innovative therapy has direct or selective effects on genes (mRNAs) that produce disease-causing proteins and is completely different from existing treatment with low-molecular-weight compounds that act on proteins, such as enzymes and receptors. Since the RNAi therapeutics is expected to significantly accelerate productivity such as increased targets and shortened period of drug discovery, it attracts the interest of researchers and the industry as innovative technology to shift the existing paradigm of drug discovery in the future.

About biopolymer

Biopolymers are polymers that mimic natural materials. Biopolymers are used in medical applications because they are safe and decompose easily in living organisms.

About Takeda

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

About Samyang

Established in 1924, Samyang is a Korean manufacturing company in chemicals, foodstuff, and pharmaceutical businesses. In pharmaceuticals, Samyang is primarily focused on drug delivery technologies and conducts global collaborations as well as internal research projects. Recently Samyang announced the expansion of Bio Pharmaceutical R&D Center to Pangyo, GyeongGi-Do, Korea. Additional information is available on its corporate website: http://www.samyang.com/


Latest Press Releases